- Red Light Holland (CSE:TRIP) begins stability testing for its psilocybin microdosing capsules
- The capsules were developed by its partner CCrest Laboratories to be distributed with NUBU Pharmaceuticals across Australasia
- Stability testing is planned for 12 months to determine the capsule’s shelf life
- Shares of Red Light Holland Stocks (CSE:TRIP) are unchanged at C$0.08
Red Light Holland (TRIP) has begun stability testing for its psilocybin microdosing capsules.
In a press release, the company said testing is planned for 12 months to determine the capsule’s shelf life.
Testing under higher temperatures and humidity conditions is also underway to expedite results so the company can obtain an import license for Nubu Pharmaceuticals, its partner in Australia.
The capsules were developed by its partner, CCrest Laboratories, and will be distributed across Australasia by Nubu Pharmaceuticals.
“Stability testing is an important stage in developing high-quality natural psilocybin microdosing capsules so we are glad to make significant progress towards the end product,” Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories, said in a statement.
Todd Shapiro, CEO of Red Light Holland, said its partnership “continues to break new grounds” and he believes Red Light Holland is the first to develop microdosing capsules from natural psilocybin truffles for the legal market.
Headquartered out of Ontario, Red Light Holland is focused on the production, growth and sale of functional mushrooms and mushroom home grow kits across North America and Europe.
The company also has a premium brand of psilocybin truffles for the legal, recreational market in the Netherlands.
Shares of Red Light Holland (TRIP) are unchanged at C$0.08.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.